How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.

Adolescent Child Craniospinal Irradiation Glioma Humans Neoplasm Recurrence, Local Re-Irradiation Retrospective Studies

5th WHO classification Dissemination Pediatric high-grade glioma Reirradiation

Journal

Journal of neuro-oncology

ISSN: 1573-7373

Titre abrégé: J Neurooncol

Pays: United States

ID NLM: 8309335

Informations de publication

Date de publication:
Sep 2022

Historique:

received: 31 05 2022

accepted: 25 06 2022

pubmed: 10 7 2022

medline: 31 8 2022

entrez: 9 7 2022

Statut: ppublish

Résumé

Recurrence incidence for paediatric/adolescent high-grade glioma (HGG) exceeds 80%. Reirradiation (reRT) palliates symptoms and delays further progression. Strategies for reRT are scarce: we retrospectively analysed our series to develop rational future approaches. We re-evaluated MRI + RT plans of 21 relapsed HGG-patients, accrued 2010-2021, aged under 18 years. All underwent surgery and RT + chemotherapy at diagnosis. Pathologic/molecular re-evaluation allowed classification based on WHO 2021 criteria in 20/21 patients. Survival analyses and association with clinical parameters were performed. Relapse after 1st RT was local in 12 (7 marginal), 4 disseminated, 5 local + disseminated. Re-RT obtained 8 SD, 1 PR, 1PsPD, 1 mixed response, 10 PD; neurological signs/symptoms improved in 8. Local reRT was given to 12, followed again by 6 local (2 marginal) and 4 local + disseminated second relapses in 10/12 re-evaluated. The 4 with dissemination had 1 whole brain, 2 craniospinal irradiation (CSI), 1 spine reRT and further relapsed with dissemination and local + dissemination in 3/four assessed. Five local + disseminated tumours had 3 CSI, 1 spine reRT, further progressing locally (2), disseminated (1), n.a. (1). Three had a third RT; three were alive at 19.4, 29, 50.3 months after diagnosis. Median times to progression/survival after re-RT were 3.7 months (0.6-16.2 months)/6.9 months (0.6-17.9 months), improved for longer interval between 1st RT and re-RT (P = 0.017) and for non-PD after reRT (P < 0.001). First marginal relapse showed potential association with dissemination after re-RT (P = 0.081). This is the biggest series of re-RT in paediatric HGG. Considering the dissemination observed at relapse, our results could prompt the investigation of different first RT fields in a randomized trial.

Identifiants

DOI: 10.1007/s11060-022-04079-4 PMID: 35809148

pubmed: 35809148

doi: 10.1007/s11060-022-04079-4

pii: 10.1007/s11060-022-04079-4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

437-445

Informations de copyright

Références

Fangusaro J (2012) Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol 2:1–10. https://doi.org/10.3389/fonc.2012.00105

doi: 10.3389/fonc.2012.00105

MacDonald TJ, Aguilera D, Kramm CM (2011) Treatment of high-grade glioma in children and adolescents. Neuro Oncol 13:1049–1058. https://doi.org/10.1093/neuonc/nor092

doi: 10.1093/neuonc/nor092 pubmed: 21784756 pmcid: 3177659

Kline C, Felton E, Allen IE, Tahir P, Mueller S (2018) Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. J Neurooncol 137:103–110. https://doi.org/10.1007/s11060-017-2701-8

doi: 10.1007/s11060-017-2701-8 pubmed: 29204840

Sturm D, Pfister SM, Jones DTW (2017) Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol 35:2370–2377. https://doi.org/10.1200/JCO.2017.73.0242

doi: 10.1200/JCO.2017.73.0242 pubmed: 28640698

Cohen AR (2022) Brain tumors in children. N Engl J Med 386:1922–1931. https://doi.org/10.1056/NEJMra2116344

doi: 10.1056/NEJMra2116344 pubmed: 35584157

Hauser P (2021) Classification and treatment of pediatric gliomas in the molecular era. Children 8:739. https://doi.org/10.3390/children8090739

doi: 10.3390/children8090739 pubmed: 34572171 pmcid: 8464723

Lucas JT Jr, Cooper DA, Hwang S, Tinkle C, Li X, Li Y, Orr B, Merchant TE, Broniscer A (2017) Prognostic relevance of treatment failure patterns in pediatric high-grade glioma: is there a role for a revised failure classification system? Int J Radiat Oncol Biol Phys 99:450–458. https://doi.org/10.1016/j.ijrobp.2017.04.039

doi: 10.1016/j.ijrobp.2017.04.039 pubmed: 28871996 pmcid: 8721563

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

doi: 10.1093/neuonc/noab106 pubmed: 34185076 pmcid: 8328013

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G (2018) Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 36:951–995. https://doi.org/10.1200/jco.2017.76.0611

doi: 10.1200/jco.2017.76.0611 pubmed: 29412784

Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, Casanova M, Pecori E, Giangaspero F, Antonelli M, Buttarelli FR, Potepan P, Pollo B, Nunziata R, Spreafico F, Podda M, Anichini A, Clerici CA, Sardi I, De Cecco L, Bode U, Bach F, Gandola L (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol 118:305–312. https://doi.org/10.1007/s11060-014-1428-z

doi: 10.1007/s11060-014-1428-z pubmed: 24696052

Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani D, Fossati-Bellani F (2005) Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 7:41–48. https://doi.org/10.1215/S1152851704000304

doi: 10.1215/S1152851704000304 pubmed: 15701281 pmcid: 1871624

Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 19:153–161. https://doi.org/10.1093/neuonc/now101

doi: 10.1093/neuonc/now101 pubmed: 27282398

Roux A, Pallud J, Saffroy R, Edjlali-Goujon M, Debily MA, Boddaert N, Sanson M, Puget S, Knafo S, Adam C, Faillot T, Cazals-Hatem D, Mandonnet E, Polivka M, Dorfmüller G, Dauta A, Desplanques M, Gareton A, Pages M, Tauziede-Espariat A, Grill J, Bourdeaut F, Doz F, Dhermain F, Mokhtari K, Chretien F, Figarella-Branger D, Varlet P (2020) High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro Oncol 22:1190–1202. https://doi.org/10.1093/neuonc/noaa024

doi: 10.1093/neuonc/noaa024 pubmed: 32025728 pmcid: 7594566

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

doi: 10.1007/s00401-016-1545-1 pubmed: 27157931

Krauze AV, Peters C, Cheng J, Ning H, Mackey M, Rowe L, Cooley-Zgela T, Smart DD, Camphausen K (2017) Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system. Radiat Oncol 12:191. https://doi.org/10.1186/s13014-017-0930-9

doi: 10.1186/s13014-017-0930-9 pubmed: 29187219 pmcid: 5707810

Navarria P, Minniti G, Clerici E, Tomatis S, Pinzi V, Ciammella P, Galaverni M, Amelio D, Scartoni D, Scoccianti S, Krengli M, Masini L, Draghini L, Maranzano E, Borzillo V, Muto P, Ferrarese F, Fariselli L, Livi L, Pasqualetti F, Fiorentino A, Alongi F, BuglionediMonale M, Magrini S, Scorsetti M (2019) Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol 142:59–67. https://doi.org/10.1007/s11060-018-03059-x

doi: 10.1007/s11060-018-03059-x pubmed: 30515706

García-Cabezas S, Rivin Del Campo E, Solivera-Vela J, Palacios-Eito A (2021) Re-irradiation for high-grade gliomas: has anything changed? World J Clin Oncol 12:767–786. https://doi.org/10.5306/wjco.v12.i9.767

doi: 10.5306/wjco.v12.i9.767 pubmed: 34631441 pmcid: 8479348

Komori T (2021) The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles. Brain Tumor Pathol. https://doi.org/10.1007/s10014-022-00428-3

doi: 10.1007/s10014-022-00428-3 pubmed: 33398472

Müller K, Scheithauer H, Pietschmann S, Hoffmann M, Rössler J, Graf N, Baumert BG, Christiansen H, Kortmann RD, Kramm CM, von Bueren AO (2014) Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 9:177. https://doi.org/10.1186/1748-717X-9-177

doi: 10.1186/1748-717X-9-177 pubmed: 25112658 pmcid: 4283148

Tsang DS, Oliveira C, Bouffet E, Hawkins C, Ramaswamy V, Yee R, Tabori U, Bartels U, Huang A, Millar BA, Crooks B, Bowes L, Zelcer S, Laperriere N (2019) Repeat irradiation for children with supratentorial high‐grade glioma. Pediatr Blood Cancer 66:e27881. https://doi.org/10.1002/pbc.27881

doi: 10.1002/pbc.27881 pubmed: 31207154

Rodriguez D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, Mackay A, Varlet P, Le Deley MC, Hargrave D, Cañete A, Massimino M, Azizi AA, Saran F, Zahlmann G, Garcia J, Vassal G, Grill J, Peet A, Dineen RA, Morgan PS, Jaspan T (2022) MRI and molecular characterization of pediatric high-grade midline thalamic gliomas: the HERBY phase II trial. Radiology 12:211464. https://doi.org/10.1148/radiol.211464

doi: 10.1148/radiol.211464

Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, Warmuth-Metz M, Kortmann RD, Pietsch T, Wolff JE (2006) Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer 95:991–997. https://doi.org/10.1038/sj.bjc.6603402

doi: 10.1038/sj.bjc.6603402 pubmed: 17047647 pmcid: 2360717

O’Leary B, Mandeville HC, Fersht N, Solda F, Mycroft J, Zacharoulis S, Vaidya S, Saran F (2016) Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. J Neurooncol 127:295–302. https://doi.org/10.1007/s11060-015-2033-5

doi: 10.1007/s11060-015-2033-5 pubmed: 26842817

Kocakavuk E, Anderson KJ, Varn FS, Johnson KC, Amin SB, Sulman EP, Lolkema MP, Barthel FP, Verhaak RGW (2021) Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet 53:1088–1096. https://doi.org/10.1038/s41588-021-00874-3

doi: 10.1038/s41588-021-00874-3 pubmed: 34045764 pmcid: 8483261

Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47. https://doi.org/10.1016/j.ejca.2016.12.007

doi: 10.1016/j.ejca.2016.12.007 pubmed: 28161497

Cacciotti C, Liu KX, Haas-Kogan DA, Warren KE (2020) Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract 8:68–74. https://doi.org/10.1093/nop/npaa063

doi: 10.1093/nop/npaa063 pubmed: 33664971 pmcid: 7906270

Lassaletta A, Strother D, Laperriere N, Hukin J, Vanan MI, Goddard K, Lafay-Cousin L, Johnston DL, Zelcer S, Zapotocky M, Rajagopal R, Ramaswamy V, Hawkins C, Tabori U, Huang A, Bartels U, Bouffet E (2018) Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer 65:e26988. https://doi.org/10.1002/pbc.26988

doi: 10.1002/pbc.26988 pubmed: 29369515

Le Tourneau C, Delord JP, Kotecki N, Borcoman E, Gomez-Roca C, Hescot S, Jungels C, Vincent-Salomon A, Cockenpot V, Eberst L, Molé A, Jdey W, Bono F, Trochon-Joseph V, Toussaint H, Zandanel C, Adamiec O, de Beaumont O, Cassier PA (2020) A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours. Br J Cancer 123:1481–1489. https://doi.org/10.1038/s41416-020-01028-8

doi: 10.1038/s41416-020-01028-8 pubmed: 32839491 pmcid: 7653034